Pain and Inflammation Research
Although separate conditions, pain and inflammation are nearly always associated with each other. Pain is defined by the International Association for the Study of Pain (IASP) as 'an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage'. Inflammation is the tissue's immunologic response to injury, characterized by mobilization of white blood cells and antibodies, swelling, and fluid accumulation.
Pain and Inflammation Research Products Areas
Products for Pain and Inflammation Research - Page 84
- Cat.No. Product Name Information/Activity
-
BCC7936
VU 29
890764-36-0
-
BCC6969
(2R,4R)-APDC
(2R,4R)-APDC is a selective group II metabotropic glutamate receptors (mGluRs) agonist. (2R,4R)-APDC has anticonvulsant and neuroprotective effects.
-
BCC6609
L-CCG-l
117857-93-9
-
BCC5691
DCG IV
DCG-IV is a potent agonist of group II mGluRs with EC50s of 0.35 and 0.09 μM for mGlu2R and mGlu3R, reapectively. DCG-IV is also a competitive antagonist at group I (IC50: mGlu1/5R=389/630 μM) and III receptors (IC50: mGlu4/6/7/8R= 22.5/39.6/40.1/32 μM). DCG-IV has anticonvulsive and neuroprotective effects.
-
BCC7614
LY 354740
Eglumegad (LY354740) is a highly potent and selective group II (mGlu2/3) receptor agonist with IC50s of 5 and 24 nM on transfected human mGlu2 and mGlu3 receptors, respectively.
-
BCC7368
LY 379268
Highly selective group II mGlu agonist
-
BCC7623
(±)-LY 395756
852679-66-4
-
BCC6758
MAP4
157381-42-5
-
BCC6925
(RS)-APICA
170847-18-4
-
BCC6871
EGLU
EGLU ((2S)-α-Ethylglutamic acid; (2S)-α-EGLU) is a potent and competitive mGluR-2 receptor antagonist. EGLU interacts with (lS,3S)-ACPD-sensitive site with a Kd value of 66 μM. EGLU is an antidepressant agent.
